CX33 - Preliminary Programme

Download the PDF programme here

Overview of CX Courses
CX Imaging Course
Stéphan Haulon, Lille, France
CX Innovation Showcase
Nick Cheshire, Imperial College, London, United Kingdom
CX St. George’s Vascular Access Course
Eric Chemla, London, United Kingdom
ilegx
Michael Edmonds, London United Kingdom
Gunnar Tepe, Rosenheim, Germany,
Dieter Mayer, Zurich, Switzerland
LINC @ CX
Dierk Scheinert, Leipzig, Germany
Andrej Schmidt, Leipzig, Germany
Training consensus update
Need for training for young vascular surgeons: The trainer’s perspective
Carlo Setacci, Siena, Italy
CX European Vascular Surgeons in Training: The trainee’s perspective
Vikas Pandey, Imperial College, London, United Kingdom
Towards consensus in training of vascular and endovascular surgery
Cliff Shearman, Southampton, United Kingdom
Percutaneous techniques and closure devices
Jon Matsumura, Madison, WI, United States
CAROTID CONSENSUS UPDATE
The value of transcranial Doppler and vascular options update
Ian Loftus, London, United Kingdom
Risk-adjusted stroke outcome benchmarks for carotid artery stenting: How do you measure up?
Jon Matsumura, Madison, WI, United States
Diffusion weighted magnetic resonance imaging using flow reversal system
tba
Tips for carotid artery stenting in the high anatomic risk patients: At least one indication for carotid artery stenting will survive
Peter Schneider, Honolulu, HI, United States
Sex inequality in carotid disease – are stents the great equalizer? Stent improvements needed
Sumaira Macdonald, Newcastle, United Kingdom
Why the attitude against carotid artery stenting is wrong: Endovascular option update
Klaus Mathias, Dortmund, Germany
CREST / ICSS: What is the clinical message? Consensus update oncarotid intervention
tba
Carotid Debate: Carotid stenting is dead and buried
For the motion:
tba
Against the motion:
tba
THORACIC CONSENSUS UPDATE
GENERAL
Aortic pathologies amenable to non stent graft treatment
Edward Diethrich, Phoenix, AZ, United States
Diagnosing Marfan syndrome and other connective tissue diseases
Roy Greenberg, Cleveland, OH, United States
Automatic monitoring of spinal fluid drainage: Safer protection for spinal cord ischaemia
Vicente Riambau, Barcelona, Spain
SVS practice guidelines on left subclavian revascularization with TEVAR: Preventing neurologic complications
Jon Matsumura, Madison, WI, United States
The role of simulators in endovascular training
Alan Lumsden, Houston, TX, United States
RELATIONSHIP TO PATHOLOGY
Should TEVAR devices be pathology specific?
Robert Morgan, London, United Kingdom
Late TEVAR complications relative to original pathology: Consensus on relationship to pathology
Matt Thompson, London, United Kingdom
TRANSECTION THORACIC AORTA
Endovascular repair of traumatic thoracic aortic injury: Clinical practice guidelines of the Society for Vascular Surgery late follow up consensus
Ron Fairman, Philadelphia, PA, United States
AORTIC DISSECTION – TYPE A
Retrograde ascending aortic dissection during or after thoracic aortic endograft implantation
Santi Trimarchi, San Donato Milanese, Italy
Surgery in Type A dissection
John Pepper, Imperial College, London, United Kingdom
Endovascular approaches in Type A dissection
Stéphan Haulon, Lille, France
Frozen elephant technique in Type A dissection
Heinz Günther Jakob, Essen, Germany
Altering the strategy for Type A repair: Planning for subsequent interventions: Consensus on Type A aortic dissection management
Roy Greenberg, Cleveland, OH, United States
Tara Mastracci, Cleveland, OH, United States
AORTIC DISSECTION – TYPE B
Residual Type B dissection after surgical repair of Type A: Incidence, prevention and management
Vicente Riambau, Barcelona, Spain
Uncomplicated type B dissection – are there any indications for early intervention
Michael Dake, Stanford, CA, United States
How distal do we need to cover? VIRTUE registry data
Matt Thompson, London, United Kingdom
Management of acute limb ischaemia
John Reidy, London, United Kingdom
Do branched/fenestrated devices have a role in chronic dissection?
Eric Verhoeven, Nürnberg, Germany
Management of visceral malperfusion syndromes and consensus on aortic dissection Type B
Ron Fairman, Philadelphia, PA, United States
THORACIC ANEURYSM – GENERAL
Overcoming access and trackability problems
Jon Matsumura, Madison, WI, United States
A new device to prevent strokes in complex TEVAR procedures
tba
Scalloped TEVAR devices for aneurysms involving the coeliac axis
Peter Taylor, London, United Kingdom
Endovascular treatment of coarctation
Shakeel Qureshi, London, United Kingdom
TEVAR long-term follow up: changes in the aorta. Is rupture prevented? Zenith LP trial status
Piotr Kasprzak, Regensburg, Germany
THE AORTIC ARCH
TEVAR with debranching
Jean-Pierre Becquemin, Créteil, France
A new device for total endovascular arch repair
Krassi Ivancev, London, United Kingdom
Chimney techniques in the aortic arch - justification of chimney or debranching techniques
Frank Criado, Baltimore, MD, United States
Single branched endografts for aortic arch aneurysms: Consensus on branched aortic arch endographs
Roy Greenberg, Cleveland, OH, United States
THORACOABDOMINAL ANEURYSMS
Durability of branched endografts
Roy Greenberg, Cleveland, OH, United States
Durability of fenestrated endografts
Stéphan Haulon, Lille, France
Techniques to reduce the risk of paraplegia in endovascular thoracoabdominal repair
Krassi Ivancev, London, United Kingdom
Top ten tips for accessing target vessels during FEVAR/target vessel loss during and following fenestrated endovascular repair of juxtarenal aneurysms
Richard McWilliams, Liverpool, United Kingdom
S. Rao Vallabhaneni, Liverpool, United Kingdom
Hybrids for thoracoabdominal aneurysms: Effect of the learning curve
Ian Loftus, London, United Kingdom
The best option for a type IV thoraco-abdominal aortic aneurysm repair – open? Hybrid? Endovascular branch graft? Consensus on thoraco-abdominal aortic aneurysm management
John Wolfe, Imperial College, London, United Kingdom
MESENTERIC/RENAL CONSENSUS UPDATE
Endovascular treatment options for visceral aneurysms
Raman Uberoi, Oxford, United Kingdom
Revascularisation of acute occlusion of the superior mesenteric artery in the endovascular era
Martin Björk, Uppsala, Sweden
Renal Debate: Renal artery revascularisation is a dead duck
For the motion:
Jon Moss, Glasgow, United Kingdom
Against the motion:
Michael Jaff, Boston, MA, United States
ABDOMINAL AORTIC ANEURYSM CONSENSUS UPDATE
Indications for aortic aneurysm surgery - the main conclusion of the UK small aneurysm trial is simplistic
Charles McCollum, Manchester, United Kingdom
Performance of Iliac side branch devices - patients with iliac/aortoiliac aneurysms and placement of side branch devices
Giovanni Torsello, Münster, Germany
Internal iliac artery management, branched graft or not: Consensus
tba
Study on infected aortic endografts
Michel Reijnen, Arnhem, Netherlands
Reducing patient harm during complex endovascular aortic reconstruction
Colin Bicknell, Imperial College, London, United Kingdom
Is extreme angulation of the proximal aortic aneurysm neck still a contra-indication for EVAR? Does it last?
Hence Verhagen, Rotterdam, Netherlands
After the trials, open repair has a resurgence
Jean-Pierre Becquemin, Créteil, France
Imaging protocol after EVAR: What can be left out, what is the absolute minimum?
Jos van den Berg, Lugano, Switzerland
Endoleak management in aortic stent graft patients with renal insufficiency
Peter Schneider, Honolulu, HI, United States
Secondary EVAR rupture after 10 years
Thomas Wyss, Chur, Switzerland
Patient preference: EVAR/OR at 10 years
tba
EVAR cost effectiveness at 10 years
David Epstein, York, United Kingdom
After the trials, what has device modification contributed to improved results?
Cook Medical: Zenith Low Profile Timothy Resch, Malmö, Sweden
Cordis: Incraft tba
Endologix: AFX tba
Gore: Excluder C3 Eric Verhoeven, Nürnberg, Germany
Lombard Medical: Aorfix tba
Medtronic: Endurant tba
Nellix tba
Trivascular: Ovation tba
Vascutek Terumo: Anaconda tba
Ruptured Aortic Aneurysm Screening
What is the status of the UK national screening programme for abdominal aortic aneurysms?
Jonothan Earnshaw, Cheltenham, United Kingdom
Are we seeing fewer ruptures yet?
Matt Thompson, London, United Kingdom
Recruitment in the IMPROVE trial
Janet Powell, Imperial College, London, United Kingdom
How to make EVAR work better in the ruptured abdominal aortic aneurysm setting
Frank Veith, New York, NY, United States
Systematic approach to ruptured aneurysm
Marc van Sambeek, Eindhoven, Netherlands
Aortic Debate: National screening will make aortic rupture a rarity
For the motion:
Brian Heather, Gloucester, United Kingdom
Against the motion:
tba
LOWER LIMB CONSENSUS UPDATE
The TASC management in 2011
tba
Do new flexible and long stents designs demand an update of the TASC femoropopliteal recommendations? TASC femoropopliteal management in 2011
Patrick Peeters, Bonheiden, Belgium
Common femoral stent
Gunnar Tepe, Rosenheim, Germany
Superficial femoral artery: Anti-coagulants, anti-thrombotics - goodbye aspirin?
Beverley Hunt, London, United Kingdom
Multicenter randomized long-term trial results showing that heparin bonding improves vascular graft patency
Jes Lindholt, Viborg, Denmark
Perhaps long segment superficial femoral artery stents fail because they provide too much scaffolding
Peter Schneider, Honolulu, HI, United States
Brachytherapy of the superficial femoral artery - revival with Rh-88?
Klaus Mathias, Dortmund, Germany
Results of a randomized trial comparing ultrasound enhanced thrombolysis versus standard thrombolysis for peripheral arterial occlusive disease (DUET study)
Jean-Paul de Vries, Nieuwegein, Netherlands
Is atherectomy a useful and cost-effective tool in lower extremity vascular disease?
Robert Morgan, London, United Kingdom
Drug-eluting balloons are clearly the best way to treat femoropopliteal occlusive disease
Gunnar Tepe, Rosenheim, Germany
Subintinal angioplasty - collateral importance
tba
VIPER trial update (6Fr Viabahn)
Richard Saxon, Oceanside, CA, United States
VIASTAR trial: Viabahn versus bare metal stents on TASC CxD lesions at one year
Johannes Lammer, Vienna, Austria
Distal endarterectomy and stent
tba
Dual component bare metal stent in the superficial femoral artery:  consensus on superficial femoral artery management
Dierk Scheinert, Leipzig, Germany
Repetitive stem cell treatment in patients with Buerger's disease is superior to any kind of conservative therapy.
Ralf Kolvenbach, Düsseldorf, Germany
Stem cell therapy in a non-university setting
Jos van den Berg, Lugano, Switzerland
Below the knee stem cells: Consensus value
Iris Baumgartner, Bern, Switzerland
What is the evidence in favour of tibial angioplasty? Consensus statement
Peter Schneider, Honolulu, HI, United States
Drug-eluting balloons: Six-month angiographic follow-up of the LEVANT I Trial
Stephan Duda, Berlin, Germany
Recanalisation and angioplasty of the pedal arteries: Endovascular consensus
Michael Lee, Dublin, Eire
Peripheral Debate: Below the knee endovascular treatment alone is of unproven value
For the motion:
tba
Against the motion:
tba

VENOUS CONSENSUS UPDATE
VENOUS DISEASE –THE BURDEN
Burden of venous disease - how to measure
Jean-Jérôme Guex, Nice, France
CT/MRI imaging in venous disease
tba
Quality of life tools in venous disease
Alun H. Davies, Imperial College, London, United Kingdom
Outcomes from a physician’s perspective and from a patient’s perspective
Michael Vasquez, North Tonawanda, NY, United States
INDICATIONS FOR TREATMENT DEPENDANT ON CEAP CLASSIFICATION
C1 – C3 Disease: Treatment consensus
Paul Pittaluga, Nice, France
C4 – C6 Disease: Treatment consensus
Eberhard Rabe, Bonn, Germany
SUMMARY OF TREATMENTS FOR PRIMARY VARICOSE VEINS
Compression: The objective and pitfalls
Andrea Nelson, Leeds, United Kingdom
Compression vs no compression after endothermal ablation
Lowell Kabnick, New York, NY, United States
Surgery has not been bettered?
Lars Rasmussen, Naestved, Denmark
Ablation is the key to successful primary varicose vein treatment
Tim Lees, Newcastle, United Kingdom
Endothermal ablation: An update
Renate van den Bos, Rotterdam, Netherlands
ASVAL and CHiVA summarised
Paul Pittaluga, Nice, France
Preservation is the key to successful primary varicose vein treatment
Jordi Maeso, Barcelona, Spain
Foam vs laser
George Geroulakos, Imperial College, London, United Kingdom
Simultaneous foam sclerotherapy and compression is the treatment of choice for venous ulcers
Jonothan Earnshaw, Gloucester, United Kingdom
Foam sclerotherapy is the panacea
Nick Morrison, Scottsdale, AZ, United States
Consensus on modes of treatment - Surgery; Laser; Radiofrequency; Sclerotherapy
tba
Updates on recurrence and its management
Marianne de Maeseneer, Antwerp, Belgium
EVVERT comparing laser and radiotherapy. An additional update on the place today of surgery and sclerotherapy
Ian Loftus, London, United Kingdom
Venous Debate: Office based vein practice wins and should do so
For the motion:
Ian Franklin, Imperial College, London, United Kingdom
Against the motion:
tba
EVIDENCE BASED MEDICINE vs ECONOMY BASED MEDICINE
Cost effectiveness of intervention for primary varicose veins
Manj Gohel, Imperial College, London, United Kingdom
Cost issues in Europe for intervention for primary varicose veins
Jean-Jérôme Guex, Nice, France
Consensus on cost effectiveness
Eberhard Rabe, Bonn, Germany
VENOUS THROMBOEMBOLISM
Anti-coagulation of your patient with a duplex proven EHIT 2
Lowell Kabnick, New York, NY, United States
LMWH (Low Molecular Weight Heparin) is better than oral coagulation in the first three months of treatment
Marc Cairols, Barcelona, Spain
ATTRACT trial updates
Anthony Comerota, Toledo, OH, United States
Dutch trial for ilio-femoral DVT
Cees Wittens, Maastricht, Netherlands
Percutaneous mechanical thrombectomy is superior to catheter directed thrombectomy alone
Peter Holt, London, United Kingdom
Angiojet vs Trellis
Gerard O’Sullivan, Galway, Eire
Stents for May-Thurner/Cockett syndrome,
tba
Reduction of venous ulcers by 50% in prevalence in ten years: Consensus on management of venous thromboembolism
Bo Eklöf, Helsingborg, Sweden
ilegx programme
Download orderform

ilegx programme